Introduction 57
Chronic infection with hepatitis C virus (HCV) affects approximately 160 million people 58 worldwide (1) and is the leading cause of cirrhosis, liver cancer and liver transplantation (2) . 59
The goal of treatment is to achieve a sustained virological response (SVR), marker of viral 60 8 All drug concentrations were fitted separately in telaprevir and boceprevir treatment groups. 145
For both Peg-IFN and RBV, the trough serum concentrations, noted C Peg-IFN (t) and C RBV (t) , 146 respectively were fitted using an exponential model to reflect the progressive increase in 147 trough drug concentrations over time: 148
Eq. (1) 149 E q . ( 2 ) 150 where C ss is the trough concentration at steady state and k the rate constant of elimination 151 which reflects the progressive increase in C(t) over time. 152
For both PI drugs, consistent with the fact that they have a short elimination half-life (22), no 153 significant increase of trough concentrations over time was observed. Therefore 154 concentrations for both telaprevir and boceprevir were fitted using a constant model, where 155 are lost with rate and produce p virions per day, which are cleared from serum with rate c. 165
The target cell level is assumed constant throughout the study period (12 weeks) and remains 166 at its pre-treatment value T 0 =c /pβ. Treatment is assumed to reduce the average rate of viral 167 production per cell from p to p(1-), where represents the drug antiviral effectivenesses, i.e., 168 = 0.99 implying the drug is 99% effective in blocking viral production. This model predicts 169 9 that VL will fall in a biphasic manner, with a rapid first phase lasting for a couple of days that 170 reduce the VL with a magnitude equal to log 10 (1-), followed by a second slower but 171 persistent second phase of viral decline with rate . Therefore a difference between = 172 99.9% and = 99.0% corresponds to a 10-fold difference in the viral production under 173 treatment and will lead to 1-log difference between the two curves of viral decline (24). We 174 fixed p and b to 100 IU/ml/cell/day and 10 -7 (IU/ml) -1 /day, respectively, without loss of 175 generality (25) . 176
The effectiveness of each drug in blocking viral production was described by an E max model 177 assuming a maximum inhibition of 100%: 178 179 E q . ( 5 ) 180 where EC 50 PI (respectively EC 50
Peg-IFN
) is the PI (resp. Peg-IFN) concentration at which the PI 181 (resp. Peg-IFN) is 50% effective, and C PI (t) (resp. C Peg-IFN (t) ) are the individual predictions 182 (see below) given by the PK models (Eq. 1 and 3). 183
The combined effect of PIs and Peg-IFN was modeled using a Bliss independent action model 184 (26) and the total efficacy (t) was given by: 185
Since the effect of RBV on the early virological response is expected to be modest (27-29) 187 we did not incorporate the effect of RBV into the reference model (Eq. 4-6). In a second step 188 we tested whether the effectiveness of RBV, also modeled using an E max model could enhance 189 the effect in blocking viral production or reduce viral infectivity, as suggested previously (30 A Wald test on the PK-VK model parameters (c, , EC 50 PI ) was used to assess the difference 217 in population parameters between the two groups. Because we previously showed that this 218 approach could lead to an inflation of the type I error in case of small sample size (N<20 per 219 group) (34), a permutation test was performed to confirm statistical significance when the 220
Wald test was significant at the level of 5%. In brief, 1,000 datasets were simulated by 221 randomly allocating patients to telaprevir or boceprevir group, maintaining a similar 222 proportion of patients allocated to each groups than in the original dataset. Then the P-value 223 of the Wald test was calculated for each simulated data set. Finally the corrected P-value of 224 the permutation test is equal to the proportion of simulated datasets having a P-value lower 225 than the one found one the original dataset. 226
Because the genetic barrier to resistance of PI (i.e., the number of change in amino acids 227 needed to generate mutants with high level of resistance) depends of HCV subgenotype and 228 therefore lead to different SVR rate, we also estimated the effect of HCV subgenotype (1a vs 229 non-1a) on viral kinetic parameters. IL28B polymorphism, which is also associated with 230 response to IFN-based therapy, was not investigated because all these patients had failed to a 231 previous bitherapy. 232
233

Prediction and comparison of individual parameters 234
Individual Empirical Bayesian Estimates (EBE) parameters for both PK and VK were 235 obtained by computing for each patient the Maximum A Posteriori (MAP) estimate. The 236 individual antiviral effectiveness at steady state, ss , of each agent was defined by: 237 238 Eq. (7) 239 Non-parametric two-sided tests (Wilcoxon test) were used to compare i) individual EBE PK 240 parameters between patients who received telaprevir vs boceprevir and between patients who 241 received Peg-IFN-α2a vs -α2b, and ii) individual EBE PK parameters between SVR and non-242 SVR patients. Because all patients were non-responder to Peg-IFN, the effect of IL28B 243 genotype on PK and VK parameters was not tested. 244
245
Results
246
Fifteen HCV genotype 1 patients were included 9 receiving telaprevir and 6 receiving 247 boceprevir. Twelve (80%) were men, with a median [min; max] age of 55 [44; 64] years. 248
Seven (47%) patients were infected with subgenotype 1a, 2 (22%) in telaprevir group and 5 249 (83%) in boceprevir group. Prior treatment responses were partial response, null response, 250 relapse and early discontinuation for adverse events in 2, 5, 6 and 2 patients, respectively. 251
Only two patients had the most favorable IL28B CC genotype (35). Main characteristics of 252 the patients are presented in Table 1 . 253
Two patients had a viral breakthrough (at weeks 3 and 8). Eleven patients received Peg-IFN-254 α2a (8 in telaprevir group and 3 in boceprevir group), 3 patients Peg-IFN-α2b (all in 255 boceprevir group) and one patient in telaprevir group did not receive any injection of Peg-IFN 256 (and this patient had a viral breakthrough at week 3). 257 After the PK parameters were estimated, the predicted individual PK time courses were 268 plugged into the PK-VK model (see methods). Baseline VL was higher in the telaprevir group 269 than in the boceprevir group, thus a treatment group effect was added on baseline VL 270 14 (V 0 telaprevir = 6.43 log 10 IU/ml vs V 0 boceprevir = 5.52 log 10 IU/ml, P=0.0001). A greater proportion 271 of patients that received boceprevir were genotype 1a relative to those that received telaprevir 272 (P=0.04). Subgenotype is an important predictor of the response to treatment, in particular 273 with telaprevir with a lower genetic barrier to resistance with genotype 1a than 1b (only one 274 nucleotide change in genotype 1a viral genomes is required to generate mutations V36M and 275 R155K/T, vs two in genotype 1b) (36). This may explain why genotype 1a patients were 276 preferentially treated with boceprevir. We did not find any significant effect of subgenotype 277 on any of the parameters. 278
The model could well describe the kinetics of HCV decline observed both during the lead-in 279 phase (in the boceprevir group) and after the initiation of the PIs (in both groups, see Fig. 2) . 280
There was no evidence of model misspecification as showed by the goodness-of-fit plot (Fig.  281 3) and all parameters could be estimated with a good precision (Table 3) . 282
The model predicted a mean EC 50
Peg-IFN equal to 106 ng/ml, leading to a low antiviral 283 effectiveness at steady state of Peg-IFN at steady state of 43.4% [0.0; 52.7], consistent with 284 the modest 0.67 log 10 IU/ml drop observed during the four weeks lead-in phase in patients 285 treated with boceprevir (Fig. 2) . 286
After PI initiation, VL declines in a biphasic manner in all patients, where a rapid first phase 287 was followed by a second slower phase. The rapid first phase was attributed to a clearance 288 rate of virus, c, equal to 3.98 day -1 and to a high level of antiviral effectivenesses for both PIs. 289
The intrinsic potency of the two molecules, as measured by the EC 50 PI , was significantly 290 higher for telaprevir than boceprevir (EC 50 telaprevir = 0.009 µmol/l vs EC 50 boceprevir = 0.04 291 µmol/l, P=0.008). Importantly the statistical significance of this difference was obtained after 292 taking into account the small sample size (see methods) and adjusted on baseline VL. between the serum exposure and its antiviral effectiveness, demonstrating that the variability 299 in drug exposure needs to be taken into account to understand the between-subject variability 300 in PIs antiviral effectiveness (Fig. 4A) . Lastly because the effectiveness of both PIs were 301 much larger than that of Peg-IFN (Fig. 4B) , the total antiviral effectiveness obtained by the 302 combination of PI and Peg-IFN was largely similar to the one obtained with the PIs only. 303
After the VL was rapidly reduced as a result of the strong antiviral effectiveness of both PIs, 304 the model predicted that a second slower phase of viral decline ensued, driven by the loss rate 305 of infected cells, . We estimated to be equal to 0.18 day -1 , corresponding to a half-life of 306 infected cells of 3.9 days, with no significant differences between patients receiving telaprevir 307 and boceprevir (P=0.5). 308
Next we investigated the relationship between the PK-VK parameters and SVR. Among the 7 309 patients (47%) who achieved SVR, 5 received telaprevir and 2 received boceprevir (56% vs 310 33%, respectively, P=0.6). As shown in Fig. 5 , neither the antiviral effectivenesses of PIs nor 311 that of Peg-IFN was significantly associated with the long term virological response. However 312 the loss rate of infected cells, , was significantly higher in patients that subsequently 313 achieved SVR (median SVR = 0.27 day -1 vs median non-SVR = 0.14 day -1 , P=0.03). 314
Lastly we verified that incorporating the effect of RBV exposure in the PK-VK model, either 315 on the block of viral production or in the decrease of viral infectivity (data not shown) did not 316 improve the fit of the data. Furthermore there was no significant association between the 317 predicted C ss RBV and long term virological response (P=0.5). 318 319 Discussion 320
Here we used a PK-VK model to provide the first detailed picture of the relationship between 321 the exposure to all drugs involved in triple therapy (Peg-IFN, RBV and telaprevir or 322 boceprevir) and the early virological response. This novel model provides important insights 323 into the understanding of the response to triple therapy in hard-to treat patients. 324
We predicted that both PIs achieved a high level of antiviral effectiveness in blocking viral 325 production that was higher than 97.9% in all patients. However telaprevir had a higher 326 intrinsic potency than boceprevir, as measured by EC 50 (P=0.008 after correcting for small 327 sample size), leading to a significantly higher level of antiviral effectiveness than boceprevir 328 ( ss telaprevir = 99.8% vs ss boceprevir = 99.0%, P=0.002) i.e. a 5-fold difference in the viral 329 production under treatment. Importantly the difference in EC 50 was obtained despite the fact 330 that the study was not randomized and that patients who received telaprevir had less favorable 331 baseline characteristics than those who received boceprevir with higher baseline VL (6.43 332 log 10 IU/ml vs 5.52 log 10 IU/ml, respectively, P<10 -4 ) and a higher proportion of null 333 responder to previous bitherapy (4/9 vs 1/6). 334
The comparison of drug's antiviral effectiveness should be taken with caution because of 335 small sample size, the absence of randomization, and the fact that only trough concentrations 336 were used to estimate the EC 50 of PI which may lead to underestimation. Yet these results 337 demonstrate for the first time a significant association between serum exposure to PI agents 338 and the antiviral effectiveness achieved. To confirm the significance of this association we 339 fitted HCV RNA data to a simplified model where drug exposure was not taken into account 340 (37). As compared to this model, we found that the PK-VK model both improved the fitting 341 criterion (BIC decreases from 181.3 to 176.3, i.e. an improvement of 5 points which is 342 regarded as positive evidence) and reduced the between-patient parameter variability by 26% 343 (ω EC 50 PI from 0.85 to 0.61), thus demonstrating that serum PK is an important predictor of the 344 antiviral effectiveness of triple therapy. 345
Our estimate that telaprevir achieves an antiviral effectiveness of 99.8% is largely similar to 346 the one found in naïve patients (15), suggesting that compensated cirrhosis does not affect the 347 maximal antiviral effectiveness of telaprevir. Whether this is also true for boceprevir is not 348 known as to our knowledge there is no published viral kinetic modeling study evaluating the 349 in vivo antiviral effectiveness of boceprevir. In order to achieve a rapid viral decline, it is important to achieve not only a high level of 358 effectiveness but also a rapid second phase of viral decline. Here the latter was rather slow in 359 both treatment groups compared to what had been than found in telaprevir treated patients, 360
and this was attributed in our model to a low loss rate of infected cells, , about three times 361 smaller than in non-cirrhotic naive-patients ( of 0.18 day -1 vs 0.60 day -1 ) (15, 16). Those 362 lower values may encompass several factors, such a lower penetration of PIs into infected 363 cells in a highly scarced liver. Because the loss rate of infected cells is strongly related to the 364 treatment duration needed to achieve SVR (15), our results suggest that the time to achieve 365 SVR in this population could be longer than what had been predicted from clinical trials (15). 366
Consistent with this prediction, the relapse rate in the CUPIC trial was equal to 41% in both 367 18 treatment groups (13), i.e., much higher than what reported in treatment experienced patients 368 phase 3 clinical trials (12% to 27%) (9, 11, 22) . 369
Regarding the use of early viral kinetic parameters for treatment prediction, we found that 370 was higher in patients that subsequently achieved SVR (median SVR = 0.27 day -1 vs median 371 non-SVR = 0.14 day -1 , P=0.03) suggesting that could be a relevant predictor of the outcome of 372 triple therapy, as it was the case for Peg-IFN/RBV bitherapy (38). In contrast there was no 373 significant relationship between antiviral effectiveness of PIs on SVR (Fig. 6A) . This absence 374 of relationship is consistent with the hypothesis that in order to achieve SVR, it is necessary 375 not only to have a high antiviral effectiveness at treatment initiation, when the viral 376 population is predominantly wild-type and drug-sensitive, but also at later times, when the 377 viral population is predominantly resistant to PI agents (39, 40) . The fact that neither Peg-IFN 378 effectiveness nor RBV were associated with SVR is more surprising, as one would expect 379 these agents to be equally active against wild-type and resistant virus. However our patient 380 population was both treatment experienced and cirrhotic, two major causes of insensitivity to 381
Peg-IFN/RBV. 382
Clearly the main limitation of this study was its small size. In a previous study we evaluated 383 by simulation the power to detect a difference of antiviral effectiveness between two 384 treatment groups for a variety of designs (34). With a design comparable to the present study, 385
i.e., 10 patients per group, 7 VL per patient and an antiviral effectiveness of 99% vs 99.9%, 386 the power to detect this difference was 100% with the same statistical method that we used in 387 this analysis. Yet, further studies on larger populations will still be needed to estimate more 388 precisely the exposure-effect relationship (Fig. 4) and other kinetic parameters involved on 389 the long-term virologic response. A second limitation is that only trough pre-dose drug 390 concentrations were collected and modeled. Thus C ss is the steady-state C trough . Moreover no 391 information was collected on treatment adherence. The data analysis did not show any signal 392 2 (22) 7 (78) 5 (83) 1 (17) 7 (47) 8 ( 
